This may help to create targeted therapy for ovarian cancer, in which angiogenesis is inhibited by a blockage of NF-κB, suppressing VEGF and IL-8 activity [27], or by targeting CXCR2, the key receptor for the GRO-alpha and IL-8 chemokine activity [28]. Here, CXCR2 is linked to ovarian cancer.